UroAlert - GU Oncology Weekly

October 31, 2024

Videos

Peer-to-Peer Clinical Conversations

2024 NCCN Guidelines Update: Metastatic Castration-Resistant Prostate Cancer Treatment - Rashid Sayyid & Zachary Klaassen

Zachary Klaassen

Rashid Sayyid and Zachary Klaassen discuss the 2024 updates to the NCCN guidelines for metastatic castration-resistant prostate cancer (mCRPC) treatment.

FGFR3 Inhibition for Upper Tract Urothelial Cancer: Phase 1b Trial Results - Surena Matin

Surena Matin

Sam Chang interviews Surena Matin about a phase 1b trial evaluating FGFR3 inhibition in localized upper tract urothelial carcinoma (UTUC).

Beyond the Abstracts

Early Adjuvant Chemotherapy Improves Survival in Muscle Invasive Bladder Cancer: A Systematic Review and Meta-analysis - Beyond the Abstract

Multiplex Imaging of Localized Prostate Tumors Reveals Altered Spatial Organization of AR-Positive Cells in the Microenvironment - Beyond the Abstract

Combining PSMA-PET and PROMISE to Re-Define Disease Stage and Risk in Patients with Prostate Cancer: A Multicentre Retrospective Study - Beyond the Abstract

Immunotherapy Plus Chemotherapy Versus Chemotherapy Alone as First-Line Treatment for Advanced Urothelial Cancer: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials - Beyond the Abstract

Conference Coverage

ASTRO 2024: Bladder Adjuvant RadioTherapy (BART): Acute and Late Toxicity from a Phase III Multicenter Randomized Controlled Trial

ASTRO 2024: Short-Term Androgen Deprivation Therapy and High-Dose Radiotherapy in Intermediate- and High-Risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase III Trial

ASTRO 2024: The Space-Time Continuum in Metastatic Castration-Sensitive Prostate Cancer: The Final Frontier?

ASTRO 2024: Initial Results of a Phase 2 Trial of Stereotactic Body Radiation Therapy, Hormone/Androgen Deprivation Therapy and Radium 223 Dichloride for Oligometastatic Castrate Sensitive Prostate Cancer (SHARP)

ASTRO 2024: Bladder Preservation - A Modern Choice for Patients

Physician-Scientist Review Articles

ESMO 2024 Quick Take Insights: A Focus on SPLASH

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

HLA-G expression associates with immune evasion muscle-invasive urothelial cancer and drives prognostic relevance.

Mortality rates in radical cystectomy patients with bladder cancer after radiation therapy for prostate cancer.

Sensitive Detection of Urothelial Cancer via High-volume Urine DNA Analysis.

The interplay of mutagenesis and ecDNA shapes urothelial cancer evolution

Sex Disparity in Non-muscle-invasive Bladder Cancer: Pitfalls of Large Population-based Data Sets and Lessons from an Integrated Analysis.

Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum-containing chemotherapy: Post hoc analysis of KEYNOTE-052 and LEAP-011.

Long-term recurrence risk, metastatic potential and length of cystoscopic surveillance of low-grade non-muscle invasive bladder cancer.

Altered immunophenotypic expression in the peripheral bladder cancer immune landscape.

Long-term oncologic outcomes and complications of robot-assisted radical cystectomy for the treatment of urothelial carcinoma of the bladder.

Bladder-preserving radiation therapy for patients with locally advanced and node-positive bladder cancer.

Trends in the use of immediate postoperative intravesical chemotherapy following transurethral resection of bladder tumors.

Primary Chemoablation of Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer With UGN-102: A Single-Arm, Open-Label, Phase 3 Trial (ENVISION).

Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274.

Artificial intelligence-based assessment of pre-operative body composition is associated with early complications after radical cystectomy.

Penile & Urethral Cancers

Impact of sarcopenia and fat distribution on outcomes in penile cancer.

Renal Cancer

Challenges and Considerations in Modern Adjuvant Therapy Trials in Renal Cell Carcinoma: A Call to Power.

Treatment Modalities and Risks of Complication for Patients With Localized Renal Cell Carcinoma Aged 75 and Older.

Factors associated with surgical refusal and non-surgical candidacy in stage 1 kidney cancer: a National Cancer Database (NCDB) analysis.

Meta-analysis and systematic review of factors predicting conversion to radical nephrectomy following robotic-assisted partial nephrectomy in renal cancer patients.

Impact of a kidney-adjusted ERAS® protocol on postoperative outcomes in patients undergoing partial nephrectomy.

Aggressiveness classification of clear cell renal cell carcinoma using registration-independent radiology-pathology correlation learning.

T1a renal cancer cryoablation - first experiences in Poland.

Beyond Index Conditions: Applying a Multimorbidity Approach to Renal Cancer Nursing.

Novel Immune Checkpoint Inhibitor Targets in Advanced or Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives.

Low Serum Alanine Aminotransferase Blood Activity Is Associated with Shortened Survival of Renal Cell Cancer Patients and Survivors: Retrospective Analysis of 1830 Patients.

Prostate Cancer

Radical Prostatectomy or Watchful Waiting in Early Prostate Cancer.

A pilot study of AI-assisted reading of prostate MRI in Organized Prostate Cancer Testing.

Diagnostic utility of prostate health index density prior to MRI-ultrasound fusion targeted biopsy.

Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS-Meet-URO 26 Real-W

Incidence and mortality of prostate cancer in France from 2010 to 2021, using a real-life database (National Health Data System - SNDS) - the CaPCo Study.

Prostate-specific Antigen at 3 Months as a Predictor of Radiologic Progression-free Survival in Metastatic Hormone-sensitive Prostate Cancer Treated with Apalutamide: Analysis of 633 Patients in a Real-world Database.

Germline DNA damage repair variants and prognosis of patients with high-risk or metastatic prostate cancer.

Identifying the best candidate for focal therapy: a comprehensive review.

The Journey of Antibody-Drug Conjugates: Lessons Learned from 40 Years of Development

Practice patterns and predictors of treatment intensification in patients with metastatic castration-sensitive prostate cancer.

AI-derived Tumor Volume from Multiparametric MRI and Outcomes in Localized Prostate Cancer.

Pelvic Lymph Node Dissection in Prostate Cancer: Update from a Randomized Clinical Trial of Limited Versus Extended Dissection.

What's in a Name? Why Words Matter in Advanced Prostate Cancer.

Safety and Efficacy of Neoadjuvant Docetaxel and Radiotherapy in Localized High-Risk Prostate Cancer: Results From a Prospective Pilot Study.

Trends in Age and Prostate-Specific Antigen at Prostate Cancer Diagnosis between 2010 and 2019.

Low SMARCD3 expression is associated with poor prognosis in patients with prostate cancer.

The Association of Statin Use With Survival Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Androgen Receptor Targeted Therapies (ART).

Evaluating Biparametric Versus Multiparametric Magnetic Resonance Imaging for Diagnosing Clinically Significant Prostate Cancer: An International, Paired, Noninferiority, Confirmatory Observer Study.

Inter-reader reliability and diagnostic accuracy of PI-RADS scoring between academic and community care networks: How wide is the gap?

Long-Term Outcomes of Prostate-Specific Membrane Antigen-PET Imaging of Recurrent Prostate Cancer.

Prostate Cancer Risk Stratification in NRG Oncology Phase III Randomized Trials Using Multimodal Deep Learning With Digital Histopathology.

Profiling of urinary extracellular vesicle protein signatures from patients with cribriform and intraductal prostate carcinoma in a cross-sectional study.

The hidden costs: a qualitative analysis exploring the experience of prostate cancer treatment-related side effects on sexual function and urinary incontinence among Black survivors and their caregivers.

Postprostatectomy Radiotherapy Timing and Long-Term Health-Related Quality of Life.

The use of focal therapy for the treatment of prostate cancer in Canada: Where are we, how did we get here, and where are we going?

Hypoxia-associated gene signatures are not prognostic in high-risk localised prostate cancers undergoing androgen deprivation therapy with radiotherapy.

Phase 2 trial of PSMA PET CT versus planar bone scan and CT in prostate cancer patients progressing while on androgen deprivation therapy.

The RECONCILE study protocol: Exploiting image-based risk stratification in early prostate cancer to discriminate progressors from non-progressors (RECONCILE).

N-linked fucosylated glycans are biomarkers for prostate cancer with a neuroendocrine and metastatic phenotype.

Upper Tract Tumors

Upper tract urothelial cancer (UTUC) genomic profiling and correlation regarding benefit of platinum-based chemotherapy.

Analysis of Neoadjuvant Chemotherapy Utilization, Pathologic Response, and Overall Survival in Upper Tract Urothelial Carcinoma.

Testicular Cancer

Comorbidities in Japanese testicular cancer survivors: A multi-institutional, cross-sectional study.

New tumor markers for testicular cancer - in the here and now and in the future.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2024 Digital Science Press, LLC